FDA approves Atebrioz for fibrodysplasia ossificans progressiva in adults, pediatric patients

FDA says Atebrioz (zilurgisertib) is approved for fibrodysplasia ossificans progressiva in adults and pediatric patients 12 years and older. The recommended dosage is 100 mg once daily.